Peru resumes trials of Chinese COVID-19 vaccines
- Nucleic acid drugs can achieve functional cure of hepatitis B
- Scientists find effects of COVID-19 infection on thyroid can last at least a year
- Gilead resubmits new HIV drug Lenacapavir marketing application
- BMJ: Cervical cancer screening may usher in a big change!
- “Magic drug” metformin may make people live to 120 years old
- Common bone density scan predicts risk of dementia later in life
Peru resumes trials of Chinese COVID-19 vaccines
Peru resumes trials of Chinese COVID-19 vaccines. Peru approves SINOPHARM to resume trials of COVID-19 vaccine and will restart procurement negotiations.
Bloomberg News on December 17, Peru’s Minister of Health Pilar Mazzetti said that the Peruvian government allowed China Sinopharm Group to resume clinical trials of the COVID-19 vaccine on Wednesday.
Mazzetti said at a TV news conference that the government will now restart vaccine procurement negotiations with Sinopharm Group. The Peruvian government has signed a preliminary agreement with Pfizer for 9.9 million doses, but due to supply issues, it is expected that deliveries in 2021 will decrease.
According to “Global Times” previously reported by multiple foreign media on the 13th, the Peruvian Ministry of Health said on the 12th that because a volunteer had a health problem, it had suspended the clinical trials of the Sinopharm China Bio-COVID-19 inactivated vaccine in the country.
According to the Wall Street Journal, Dr. Germán Málaga, a researcher at the University of Cayetano Heredia in Peru, who conducted the vaccine trial, said that a 64-year-old volunteer had complications with “neurological symptoms” and decreased leg strength. , Some problems occurred in the operation.
However, Dr. Málaga told the local media RPP Noticias that he did not believe that the volunteer’s health problems were caused by the vaccine, but he needed more information.
Disclaimer of medicaltrend.org
